E-ISSN 2149-388X | ISSN 2149-0430
 

Original Research 


The Use of Free-Total Prostate Specific Antigen Ratio in Screening Prostate Cancer in Men with Specific Elevations of Prostate Specific Antigen

Chinwe Ewenighi, Uchechukwu Dimkpa, Joel Onyeanusi, Linus Onoh, Gladys Onoh, Nma Oti, Linda Obasi, Uchechukwu Ezeugwu.

Cited by (1)

Abstract
Aim: To evaluate the diagnostic performance of free-total PSA ratio using the criteria of total PSA > 4.0 ng/ml as the cut-off for prostate cancer diagnosis in men. Method: A total of sixty patients (mean age 58.03 9.82) were recruited as test subjects from the cancer unit of National Obstetric Fistula Center (NOFIC), Abakaliki, Ebonyi State, Nigeria. All the patients had total PSA value above 4.0ng/ml. Free and total PSA estimations were done using the principle of Enzyme Linked Immunosorbent Assay (ELISA). Result: Free-total PSA ratio indicated high sensitivity (98.2% and 98.2%), specificity (87.9% and 82.9%) and positive predictive values (93.3% and 90%) for detecting undiagnosed prostate cancer at cut-offs of 0.25 and 0.19 respectively. High sensitivity (97.6%) and moderate specificity (61.7%) and positive predictive value (70.0%) were observed at cut off of 0.10. Using the free-total PSA ratio cut-off of ≤ 0.10 for prostate cancer, 70% of the test subjects were diagnosed of prostate cancer, on the other hand when a cutoff of > 0.25 was used, 6.7% of the test subjects were diagnosed of a possible benign prostatic hyperplasia.
Conclusion: Free-total PSA ratio is a highly sensitive, specific and useful diagnostic tool alternative to total PSA assay for the screening of undiagnosed prostate cancer. Furthermore, it is highly predictive of the risk for developing prostate cancer at specific cutoff levels.

Key words: : Prostate-Specific Antigen (PSA), Free-Total PSA Ratio, Prostate Cancer


 
ARTICLE TOOLS
Abstract
PDF Fulltext
Print this article Print this Article
How to cite this articleHow to cite this article
Citation Tools
Related Records
 Articles by Chinwe Ewenighi
Articles by Uchechukwu Dimkpa
Articles by Joel Onyeanusi
Articles by Linus Onoh
Articles by Gladys Onoh
Articles by Nma Oti
Articles by Linda Obasi
Articles by Uchechukwu Ezeugwu
on Google
on Google Scholar
Article Statistics
 Viewed: 2092
Downloaded: 453
Cited: 1

REFERENCES
1. National Cancer Institute. Prostate specific antigen test. Reviewed 2012. Accessed from http:// www.cancer.gov/PSA on 11th May, 2014.
2. Hoffman RM, Clannon DL, Littenberg B, Frank JJ, Pierce JC. Using the free to total prostate specific antigen ratio to detect prostate cancer in men with non-specific elevations of prostate specific antigen level. J Gen Intern Med. 2000; 15 (10):739-748. [DOI via Crossref]    [Pubmed]    [PMC Free Fulltext]   
3. Lilja H, Christensson A, Dahlén U, et al. Prostate-specific antigen in serum occurs predominantly in complex with α1- antichymotrypsin. Clin Chem. 1991; 37:1618-25. [Pubmed]   
4. Stenman UH, Leinonen J, Alfthan H, Rannikko S, Tuhkanen K, Alfthan O, et al. A complex between prostate-specific antigen and α1-antichymotrypsin is the major form of prostatespecific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res. 1991; 51:222-6. [Pubmed]   
5. Christensson A, Laurell CB, Lilja H, et al. Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors. Eur J Biochem. 1990;194:755-63. [DOI via Crossref]    [Pubmed]   
6. McCormack RT, Rittenhouse HG, Finlay JA, et al. Molecular forms of prostate-specific antigen and the human kallikrein gene family: a new era. Urology. 1995; 45:729-44. [DOI via Crossref]   
7. Lilja H, et al. Regulation of the enzymatic activity of prostate-specific antigen and its reactions with extracellular protease inhibitors in prostate cancer. Scand J Clin Lab Invest Suppl. 1995; 220:47-56. [Pubmed]   
8. Leinonen J, Lövgren T, Vornanen T, Stenman UH, et al. Double-label time-resolved immunofluorometric assay of prostate-specific antigen and of its complex with α1- antichymotrypsin. Clin Chem. 1993; 39:2098-103. [Pubmed]   
9. Christensson A, Björk T, Nilsson O, Dahlén U, Matikainen MT, et al. Serum prostate specific antigen complexed to alpha 1-antichymotrypsin as an indicator of prostate cancer. J Urol.1993; 150(1):100-105. . [Pubmed]   
10. Mettlin C, Jones G, Averette H, Gusberg SB, Murphy GP, et al. Defining and updating the American Cancer Society guidelines for the cancer related check-up: prostate and endometrial cancers. CA Cancer J Clin. 1993; 43:42-6. [DOI via Crossref]    [Pubmed]   
11. American Urological Association. Early detection of prostate cancer and use of transrectal ultrasound. Baltimore, Md: Williams & Wilkins; 1992. In: American Urological Association 1992 Policy Statement Book.
12. PDQ. (Physician Data Query) [Database online]. Bethesda, Md: National Cancer Institute: 1984 - [updated 9/99]. Screening for prostate cancer. Available from: National Cancer Institute; National Library of Medicine, Bethesda, Md: CDP Technologies, Inc., New York, NY; Lexis-Nexis, Miamisburg, Ohio.
13. American College of Physicians. Screening for prostate cancer. Ann Intern Med. 1997; 126:480-4. [DOI via Crossref]   
14. U.S. Preventive Services Task Force. Guide to clinical preventive services. 2nd ed. Baltimore: Williams & Wilkins; 1996.
15. Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. New England Journal of Medicine. 2004; 350(22):2239-2246. [DOI via Crossref]    [Pubmed]   
16. Vessella RL, Lange PH, et al. Issues in the assessment of prostate-specific antigen immunoassays. An update. Urol Clin North Am. 1997; 24:261-8. [DOI via Crossref]   
17. Walz J, Haese A, Scattoni A, et al. Percent Free ProstateSpecific Antigen (PSA) is an accurate predictor of prostate cancer risk in men with serum PSA 2.5 ng/mL and Lower. Cancer. 2008; 113 (10):2695-2703. [DOI via Crossref]    [Pubmed]   
18. Demura H, Nakamura M, Hasumi H, et al. Effectiveness of percent free prostate specific antigen as a predictor of prostate cancer detection on repeat biopsy. Int J Urol. 2004; 11(7):494- 500. [DOI via Crossref]    [Pubmed]   
19. Mitrunen K, Pettersson K, Piironen T, et al. A novel duallabel one-step immunoassay for simultaneous measurement of free and total PSA concentrations and ratios in serum. Clin Chem 1995; 41:1115-1120. [Pubmed]   
20. Demura T, Shinohara N, Tanaka M, et al. Ratio of free and total prostate-specific antigen: A method of detecting prostate cancer in the cases with PSA levels of 10ng/mL or lower. J Urol. 1996; 155(suppl):S368A.
21. Mione R, Barioli P, Barichello M, Zattoni F, Prayer-Galetti T, Plebani M, Aimo G, Terrone C, Manferrari F, Madeddu G, Caberlotto L, Fandella A, Pianon C, Vianello L, Gion M. Prostate cancer probability after total PSA and percent free PSA determination. Int J Biol Markers. 1998; 13(2):77-86. [Pubmed]   
22. Schröder FH, Hugosson J, Roobol MJ, et al. Prostate-cancer mortality at 11 years of follow-up. New England Journal of Medicine. 2012; 366(11):981-990 [DOI via Crossref]    [Pubmed]   
23. Catalona WJ, Richie JP, Ahmann FR, et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol. 1994; 151:1283-90. [Pubmed]   
24. Thiel RE, Oesterling JE, Wojno KJ, et al. A multicenter comparison of the diagnostic performance of free PSA. Urology 48(6A suppl):S45-S50, 1996.
25. Bangma CH, Rietbergen BW, Kranse R, et al. The free-tototal prostate specific antigen ratio improves the specificity of prostate specific antigen in screening for prostate cancer in the general population. J Urol. 1997; 157:2191-2196. [DOI via Crossref]   
26. Oesterling JE, Jacobsen SJ, Klee GG, et al. Free, complexed and total serum prostate specific antigen: the establishment of appropriate reference ranges for their concentrations and ratios. J Urol. 1995; 154:1090-1095. [DOI via Crossref]   

This Article Cited By the following articles

Successful Evaluation of Biphasic T-wave of Wellens Syndrome in the Emergency Department.
Acta informatica medica : AIM : journal of the Society for Medical Informatics of Bosnia and Herzegovina : časopis Druš 2016; 24(1): 72-3.

1
 
How to Cite this Article
Pubmed Style

Chinwe Ewenighi, Uchechukwu Dimkpa, Joel Onyeanusi, Linus Onoh, Gladys Onoh, Nma Oti, Linda Obasi, Uchechukwu Ezeugwu. The Use of Free-Total Prostate Specific Antigen Ratio in Screening Prostate Cancer in Men with Specific Elevations of Prostate Specific Antigen. Ulutas Med J. 2015; 1(2): 31-35. doi:10.5455/umj.20150518015721


Web Style

Chinwe Ewenighi, Uchechukwu Dimkpa, Joel Onyeanusi, Linus Onoh, Gladys Onoh, Nma Oti, Linda Obasi, Uchechukwu Ezeugwu. The Use of Free-Total Prostate Specific Antigen Ratio in Screening Prostate Cancer in Men with Specific Elevations of Prostate Specific Antigen. http://www.ulutasmedicaljournal.com/?mno=188729 [Access: December 12, 2018]. doi:10.5455/umj.20150518015721


AMA (American Medical Association) Style

Chinwe Ewenighi, Uchechukwu Dimkpa, Joel Onyeanusi, Linus Onoh, Gladys Onoh, Nma Oti, Linda Obasi, Uchechukwu Ezeugwu. The Use of Free-Total Prostate Specific Antigen Ratio in Screening Prostate Cancer in Men with Specific Elevations of Prostate Specific Antigen. Ulutas Med J. 2015; 1(2): 31-35. doi:10.5455/umj.20150518015721



Vancouver/ICMJE Style

Chinwe Ewenighi, Uchechukwu Dimkpa, Joel Onyeanusi, Linus Onoh, Gladys Onoh, Nma Oti, Linda Obasi, Uchechukwu Ezeugwu. The Use of Free-Total Prostate Specific Antigen Ratio in Screening Prostate Cancer in Men with Specific Elevations of Prostate Specific Antigen. Ulutas Med J. (2015), [cited December 12, 2018]; 1(2): 31-35. doi:10.5455/umj.20150518015721



Harvard Style

Chinwe Ewenighi, Uchechukwu Dimkpa, Joel Onyeanusi, Linus Onoh, Gladys Onoh, Nma Oti, Linda Obasi, Uchechukwu Ezeugwu (2015) The Use of Free-Total Prostate Specific Antigen Ratio in Screening Prostate Cancer in Men with Specific Elevations of Prostate Specific Antigen. Ulutas Med J, 1 (2), 31-35. doi:10.5455/umj.20150518015721



Turabian Style

Chinwe Ewenighi, Uchechukwu Dimkpa, Joel Onyeanusi, Linus Onoh, Gladys Onoh, Nma Oti, Linda Obasi, Uchechukwu Ezeugwu. 2015. The Use of Free-Total Prostate Specific Antigen Ratio in Screening Prostate Cancer in Men with Specific Elevations of Prostate Specific Antigen. THE ULUTAS MEDICAL JOURNAL, 1 (2), 31-35. doi:10.5455/umj.20150518015721



Chicago Style

Chinwe Ewenighi, Uchechukwu Dimkpa, Joel Onyeanusi, Linus Onoh, Gladys Onoh, Nma Oti, Linda Obasi, Uchechukwu Ezeugwu. "The Use of Free-Total Prostate Specific Antigen Ratio in Screening Prostate Cancer in Men with Specific Elevations of Prostate Specific Antigen." THE ULUTAS MEDICAL JOURNAL 1 (2015), 31-35. doi:10.5455/umj.20150518015721



MLA (The Modern Language Association) Style

Chinwe Ewenighi, Uchechukwu Dimkpa, Joel Onyeanusi, Linus Onoh, Gladys Onoh, Nma Oti, Linda Obasi, Uchechukwu Ezeugwu. "The Use of Free-Total Prostate Specific Antigen Ratio in Screening Prostate Cancer in Men with Specific Elevations of Prostate Specific Antigen." THE ULUTAS MEDICAL JOURNAL 1.2 (2015), 31-35. Print. doi:10.5455/umj.20150518015721



APA (American Psychological Association) Style

Chinwe Ewenighi, Uchechukwu Dimkpa, Joel Onyeanusi, Linus Onoh, Gladys Onoh, Nma Oti, Linda Obasi, Uchechukwu Ezeugwu (2015) The Use of Free-Total Prostate Specific Antigen Ratio in Screening Prostate Cancer in Men with Specific Elevations of Prostate Specific Antigen. THE ULUTAS MEDICAL JOURNAL, 1 (2), 31-35. doi:10.5455/umj.20150518015721